What is IgA (Immunoglobulin A) nephropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is IgA Nephropathy?

IgA nephropathy is an autoimmune kidney disease characterized by the deposition of immunoglobulin A (IgA) in the glomerular mesangium, making it the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease that progresses to end-stage renal disease in 20-40% of patients within 20 years of diagnosis. 1, 2, 3

Pathophysiology

The disease involves a multi-step autoimmune process where galactose-deficient IgA1 (Gd-IgA1) antibodies form immune complexes that deposit in the kidney's glomerular mesangium, triggering complement-mediated inflammation and progressive kidney damage 4, 3. The definitive diagnostic feature is mesangial dominant or co-dominant IgA deposits on kidney biopsy, typically accompanied by C3 co-deposition, while C1q is less commonly present (which helps distinguish it from lupus nephritis) 5, 6.

Clinical Presentation

Common Manifestations

  • Episodic gross hematuria occurs in 40-50% of cases, often following upper respiratory infections 5
  • Persistent microscopic hematuria with or without proteinuria is the hallmark presentation 2, 7
  • Proteinuria serves as the best marker for disease progression and treatment response 7
  • The disease predominantly affects young males 2

Family History Considerations

A family history of hematuria or renal failure may occur in isolated cases, though this is not typical 5.

Diagnostic Approach

When to Suspect IgA Nephropathy

Proceed with kidney biopsy when persistent hematuria with proteinuria and concern for progressive kidney disease is present 5. Kidney biopsy remains the gold-standard diagnostic test, as no biomarker is sufficiently specific and sensitive to replace it 8, 3.

Histologic Assessment

Following biopsy-confirmed diagnosis, histologic scoring via the MEST-C system (mesangial and endocapillary hypercellularity, segmental glomerulosclerosis, interstitial fibrosis/tubular atrophy, and crescents) is essential to assess disease prognosis 1. Electron microscopy reveals electron-dense deposits in the mesangium 5, 6.

Critical Differential Diagnoses

  • Thin basement membrane disease: Distinguished by gross hematuria in <10% of patients, positive family history of hematuria but typically negative family history of renal failure 5
  • Alport syndrome: May present with episodic gross hematuria, positive family history of renal failure, and deafness in X-linked inheritance patterns 5
  • Lupus nephritis: More commonly shows C1q deposition compared to IgA nephropathy 6

Exclude Secondary Causes

Always assess for conditions causing secondary IgA deposition, including systemic lupus erythematosus, chronic liver disease (particularly cirrhosis), inflammatory bowel disease, infections, tumors, and rheumatic diseases 5, 6, 2.

Risk Stratification for Disease Progression

High-Risk Clinical Features

Patients with the following features at diagnosis are at high risk for progressive kidney disease 5, 6, 2:

  • Proteinuria >1 g/day (persistent protein excretion is the strongest modifiable risk factor) 8
  • Uncontrolled hypertension 5, 8
  • Elevated serum creatinine at presentation 2
  • eGFR <30 ml/min per 1.73 m² 1

High-Risk Histologic Features

Progression correlates more closely with tubulointerstitial lesions than glomerular lesions 2:

  • Glomerulosclerosis
  • Tubular atrophy/interstitial fibrosis
  • Extension of immune deposits to the perivascular space
  • Crescent formation

Prognostic Tools

The International IgAN Prediction Tool (available at Calculate by QxMD) provides valuable prognostic information, though neither this calculator, the MEST-C score, nor the presence of crescents can currently determine the likely impact of specific treatment regimens 1.

Common Pitfalls

Never rely on clinical features alone to exclude IgA nephropathy, as the presentation overlaps significantly with other glomerular diseases 5. The diagnosis requires kidney biopsy confirmation with demonstration of mesangial IgA deposits 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical features and natural history of IgA nephropathy.

Annales de medecine interne, 1999

Research

IgA Nephropathy: An Interesting Autoimmune Kidney Disease.

The American journal of the medical sciences, 2021

Guideline

Diagnosing and Managing IgA Nephropathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

IgA Nephropathy Pathogenesis and Clinical Implications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

IgA nephropathy in adults-treatment standard.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.